36 related articles for article (PubMed ID: 20605198)
1. An actionable test using loss of heterozygosity in identifying high-risk oral premalignant lesions.
Liu KYP; Lu XJD; Cheng YL; Klieb H; Ng S; McNeil K; Karsan A; Poh CF
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Dec; ():. PubMed ID: 29428696
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the accuracy of biparametric MRI/TRUS fusion-guided biopsy for index tumor evaluation using postoperative pathology specimens.
Shimizu R; Morizane S; Yamamoto A; Yamane H; Nishikawa R; Kimura Y; Yamaguchi N; Hikita K; Honda M; Takenaka A
BMC Urol; 2024 Apr; 24(1):79. PubMed ID: 38575912
[TBL] [Abstract][Full Text] [Related]
3. Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques.
Reynolds T; Riddick G; Meyers G; Gordon M; Flores Monar GV; Moon D; Moon C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203643
[TBL] [Abstract][Full Text] [Related]
4. Qualification of the Microsatellite Instability Analysis (MSA) for Bladder Cancer Detection: The Technical Challenges of Concordance Analysis.
Reynolds T; Bertsche K; Moon D; Moon C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203379
[TBL] [Abstract][Full Text] [Related]
5. Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection.
Reynolds T; Gordon M; Monar GVF; Moon D; Moon C
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686456
[TBL] [Abstract][Full Text] [Related]
6. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer.
Hayashi Y; Fujita K; Sakai K; Adomi S; Banno E; Nojima S; Tomiyama E; Matsushita M; Kato T; Hatano K; Kawashima A; Minami T; Morii E; Uemura H; Nishio K; Nonomura N
Sci Rep; 2022 Oct; 12(1):16642. PubMed ID: 36198773
[TBL] [Abstract][Full Text] [Related]
7. Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.
Lokeshwar SD; Lopez M; Sarcan S; Aguilar K; Morera DS; Shaheen DM; Lokeshwar BL; Lokeshwar VB
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681556
[TBL] [Abstract][Full Text] [Related]
8. Activation of PPARγ in bladder cancer via introduction of the long arm of human chromosome 9.
Shimizu R; Ohira T; Yagyu T; Yumioka T; Yamaguchi N; Iwamoto H; Morizane S; Hikita K; Honda M; Takenaka A; Kugoh H
Oncol Lett; 2022 Mar; 23(3):92. PubMed ID: 35154423
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions.
Moon C; Gordon M; Moon D; Reynolds T
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884669
[TBL] [Abstract][Full Text] [Related]
10. Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.
Shih KW; Chen WC; Chang CH; Tai TE; Wu JC; Huang AC; Liu MC
Aging Dis; 2021 Jun; 12(3):868-885. PubMed ID: 34094648
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.
Knowles MA; Hurst CD
Nat Rev Cancer; 2015 Jan; 15(1):25-41. PubMed ID: 25533674
[TBL] [Abstract][Full Text] [Related]
12. TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo.
Shan Z; Shakoori A; Bodaghi S; Goldsmith P; Jin J; Wiest JS
PLoS One; 2013; 8(6):e66114. PubMed ID: 23776618
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and spectrum of microsatellite alterations in nonmuscle invasive bladder cancers.
Legrand G; Soliman H; Dubosq F; Vérine J; Desgrandchamps F; de Thé H; Mongiat-Artus P; Ploussard G
Am J Cancer Res; 2011; 1(5):595-603. PubMed ID: 21994900
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22.
Ploussard G; Soliman H; Dubosq F; Méria P; Vérine J; Desgrand-Champs F; Dethé H; Mongiat-Artus P
Am J Cancer Res; 2011; 1(4):498-507. PubMed ID: 21984968
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer.
Ploussard G; Dubosq F; Soliman H; Verine J; Desgrandchamps F; De Thé H; Mongiat-Artus P
Urology; 2010 Aug; 76(2):513.e13-8. PubMed ID: 20605198
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.
Simoneau M; LaRue H; Aboulkassim TO; Meyer F; Moore L; Fradet Y
Oncogene; 2000 Dec; 19(54):6317-23. PubMed ID: 11175346
[TBL] [Abstract][Full Text] [Related]
17. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer.
Cai T; Nesi G; Dal Canto M; Tinacci G; Mondaini N; Piazzini M; Geppetti P; Bartoletti R
J Urol; 2010 May; 183(5):1738-43. PubMed ID: 20299058
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer.
Ozen H
Curr Opin Oncol; 1998 May; 10(3):273-8. PubMed ID: 9619365
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
